Cargando…

Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator

Fibrosis is one of the key factors that lead to the immune exclusion of solid tumors. Although degradation of fiber is a promising strategy, its application was still bottlenecked by the side effects of causing metastasis, resulting in the failure of immunotherapy. Here, we developed an antimetastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Jingwen, Zhu, Chenfei, Huang, Ying, Li, Quanhao, Li, Jing, Wang, Zheng, Wang, Yixin, Zhou, Zhanwei, Sun, Minjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372828/
https://www.ncbi.nlm.nih.gov/pubmed/37521859
http://dx.doi.org/10.1016/j.apsb.2022.12.012
_version_ 1785078438772604928
author Dong, Jingwen
Zhu, Chenfei
Huang, Ying
Li, Quanhao
Li, Jing
Wang, Zheng
Wang, Yixin
Zhou, Zhanwei
Sun, Minjie
author_facet Dong, Jingwen
Zhu, Chenfei
Huang, Ying
Li, Quanhao
Li, Jing
Wang, Zheng
Wang, Yixin
Zhou, Zhanwei
Sun, Minjie
author_sort Dong, Jingwen
collection PubMed
description Fibrosis is one of the key factors that lead to the immune exclusion of solid tumors. Although degradation of fiber is a promising strategy, its application was still bottlenecked by the side effects of causing metastasis, resulting in the failure of immunotherapy. Here, we developed an antimetastatic polymer (HPA) for the delivery of chemo-drug and antifibrotic siPAI-1 to form the nano-permeator. Nano-permeator shrank after protonation and deeply penetrated into the tumor core to down-regulate the expression of PAI-1 for antifibrosis, and further promoted the sustained infiltration and activation of T cells for killing tumor cells. Moreover, metastasis after fiber elimination was prevented by multivalent CXCR4 antagonistic HPA to reduce the attraction of CXCL12 secreted by distant organs. The administration of stroma-alleviated immunotherapy increased the infiltration of CD8(+) T cells to 52.5% in tumor tissues, inhibiting nearly 90% metastasis by HPA in distant organs. The nano-permeator reveals the mechanism and correlation between antifibrosis and antimetastasis and was believed to be the optimizing immunotherapy for solid fibrotic tumors.
format Online
Article
Text
id pubmed-10372828
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103728282023-07-28 Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator Dong, Jingwen Zhu, Chenfei Huang, Ying Li, Quanhao Li, Jing Wang, Zheng Wang, Yixin Zhou, Zhanwei Sun, Minjie Acta Pharm Sin B Original Article Fibrosis is one of the key factors that lead to the immune exclusion of solid tumors. Although degradation of fiber is a promising strategy, its application was still bottlenecked by the side effects of causing metastasis, resulting in the failure of immunotherapy. Here, we developed an antimetastatic polymer (HPA) for the delivery of chemo-drug and antifibrotic siPAI-1 to form the nano-permeator. Nano-permeator shrank after protonation and deeply penetrated into the tumor core to down-regulate the expression of PAI-1 for antifibrosis, and further promoted the sustained infiltration and activation of T cells for killing tumor cells. Moreover, metastasis after fiber elimination was prevented by multivalent CXCR4 antagonistic HPA to reduce the attraction of CXCL12 secreted by distant organs. The administration of stroma-alleviated immunotherapy increased the infiltration of CD8(+) T cells to 52.5% in tumor tissues, inhibiting nearly 90% metastasis by HPA in distant organs. The nano-permeator reveals the mechanism and correlation between antifibrosis and antimetastasis and was believed to be the optimizing immunotherapy for solid fibrotic tumors. Elsevier 2023-07 2022-12-21 /pmc/articles/PMC10372828/ /pubmed/37521859 http://dx.doi.org/10.1016/j.apsb.2022.12.012 Text en © 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Dong, Jingwen
Zhu, Chenfei
Huang, Ying
Li, Quanhao
Li, Jing
Wang, Zheng
Wang, Yixin
Zhou, Zhanwei
Sun, Minjie
Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator
title Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator
title_full Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator
title_fullStr Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator
title_full_unstemmed Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator
title_short Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator
title_sort reversing the pai-1-induced fibrotic immune exclusion of solid tumor by multivalent cxcr4 antagonistic nano-permeator
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372828/
https://www.ncbi.nlm.nih.gov/pubmed/37521859
http://dx.doi.org/10.1016/j.apsb.2022.12.012
work_keys_str_mv AT dongjingwen reversingthepai1inducedfibroticimmuneexclusionofsolidtumorbymultivalentcxcr4antagonisticnanopermeator
AT zhuchenfei reversingthepai1inducedfibroticimmuneexclusionofsolidtumorbymultivalentcxcr4antagonisticnanopermeator
AT huangying reversingthepai1inducedfibroticimmuneexclusionofsolidtumorbymultivalentcxcr4antagonisticnanopermeator
AT liquanhao reversingthepai1inducedfibroticimmuneexclusionofsolidtumorbymultivalentcxcr4antagonisticnanopermeator
AT lijing reversingthepai1inducedfibroticimmuneexclusionofsolidtumorbymultivalentcxcr4antagonisticnanopermeator
AT wangzheng reversingthepai1inducedfibroticimmuneexclusionofsolidtumorbymultivalentcxcr4antagonisticnanopermeator
AT wangyixin reversingthepai1inducedfibroticimmuneexclusionofsolidtumorbymultivalentcxcr4antagonisticnanopermeator
AT zhouzhanwei reversingthepai1inducedfibroticimmuneexclusionofsolidtumorbymultivalentcxcr4antagonisticnanopermeator
AT sunminjie reversingthepai1inducedfibroticimmuneexclusionofsolidtumorbymultivalentcxcr4antagonisticnanopermeator